Evaluation of Bone-Anchored Hearing Instruments in Chronic Otitis Media: A Multicenter Prospective Study


Creative Commons License

Ardıç F. N., GÜLMEZ M. İ., Okuyucu Ş., ŞAHİN M. İ., Yılmazer A. B., ÖZMEN Ö. A., ...Daha Fazla

Turkish Archives of Otorhinolaryngology, cilt.63, sa.1, ss.10-15, 2025 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.4274/tao.2025.2024-12-6
  • Dergi Adı: Turkish Archives of Otorhinolaryngology
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.10-15
  • Anahtar Kelimeler: Chronic otitis media, hearing loss, bone-anchored hearing aids, hearing rehabilitation, quality of life
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: This study aims to assess the effectiveness of bone-anchored hearing instruments (BAHIs) in patients with chronic otitis media (COM), using objective and subjective measures. It is a multicenter, prospective trial involving patients with COM who have undergone surgical treatment and have been rehabilitated using BAHIs. Methods: COM Questionnaire-12 (COMQ-12), Speech, Spatial, and Qualities of Hearing Scale (SSQ), World Health Organization (WHO) Quality of Life-BREF questionnaire, and audiometric tests were used for assessment. Results: Twenty-eight patients were included. The average duration of COM was 20.1±13.32 years. Among the patients, 60.7% (17) were using hearing aids, with a mean usage duration of 10.8±10.7 years (ranging from 1 to 36 years). Seven patients received the PONTO device, two received the BAH aid (BAHA) connect system, and 19 were implanted with the BAHA attract system. COMQ-12, SSQ, WHO questionaries, and audiometric tests showed significant improvement, and the results were found stable during follow-up. Conclusion: This study reinforces the effectiveness of BAHIs in improving hearing thresholds and quality of life for patients with COM.